Trevi Therapeutics, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing Haduvio, oral nalbuphine ER, for chronic cough indications including IPF-related chronic cough, non-IPF interstitial lung disease, and refractory chronic cough. Its 8-K filings report financial results, clinical development updates, FDA meeting disclosures, and material events related to the Haduvio program.
The company’s SEC record also includes registration and offering materials for common stock financings, underwriting agreements, and proxy disclosures covering director elections, executive compensation, governance matters, and equity-based compensation. These filings describe Trevi’s capital structure, development-stage operating profile, and public-company governance.
Trevi Therapeutics, Inc. director Michael Thomas Heffernan reported exercising stock options for a total of 39,473 shares of common stock on September 15, 2026, at exercise prices of $3.04 and $3.33 per share. On the same date, he sold 39,473 shares of common stock in transactions that included sales at a weighted average price of $15.09 per share, with prices ranging from $14.80 to $15.69, and additional small sales at $15.88 per share. The exercise and subsequent sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2026. The options exercised were originally granted in 2017 and would otherwise have expired in 2027.
Trevi Therapeutics, Inc. (TRVI) received a Rule 144 notice from director Michael Heffernan for a proposed sale of 39,473 shares of common stock. The shares are held through Morgan Stanley Smith Barney LLC and have an indicated aggregate market value of $627,225.97 as of September 15, 2026.
The shares to be sold were acquired on September 15, 2026 through an exercise of stock options from the issuer for cash, and are proposed to be sold on Nasdaq.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease and refractory chronic cough. For the three months ended June 30, 2026, it recorded a net loss of $17,797 (in thousands), wider than $12,301 (in thousands) a year earlier, as research and development expenses increased to $15,152 (in thousands) and general and administrative expenses to $5,357 (in thousands).
Spending rose primarily to support the new Phase 3 OCEAN-1 trial in IPF-related chronic cough, preparation for the Phase 3 OCEAN-2 trial, the Phase 2b LAKE trial in refractory chronic cough and Phase 1 NDA-supportive studies. As of June 30, 2026, Trevi held $318.9 million in cash, cash equivalents and marketable securities and had an accumulated deficit of $360.8 million, and it believes existing liquidity will fund operating and capital needs for at least 12 months while it advances these late-stage programs.
Trevi Therapeutics reported second-quarter 2026 results and progress on Haduvio, its oral nalbuphine ER program for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease and refractory chronic cough. The company initiated the Phase 3 OCEAN-1 trial in IPF-related chronic cough and the Phase 2b LAKE trial in refractory chronic cough; the Phase 3 OCEAN-2 trial is expected to start in the third quarter of 2026, with topline data from OCEAN-2 and LAKE expected in the second half of 2027 and from OCEAN-1 in the first half of 2028.
Cash, cash equivalents and marketable securities totaled $318.9 million following an April 2026 underwritten offering that generated about $162.3 million in net proceeds, which the company expects to extend its cash runway into 2030 and fund multiple Haduvio development programs. In the quarter, research and development expenses rose to $15.2 million, general and administrative expenses to $5.4 million, and net loss to approximately $17.8 million, or $0.11 per share.
FMR LLC and Abigail P. Johnson report passive ownership in Trevi Therapeutics, Inc.12,562,839.08 shares, representing 8.8% of Trevi’s common stock, with sole dispositive power over these shares and no shared voting or dispositive power. Abigail P. Johnson is reported as having sole dispositive power over the same 12,562,839.08 shares and a corresponding 8.8% stake. One or more other persons may receive dividends or sale proceeds from these securities, but no other person holds more than five percent of the outstanding common stock.
Trevi Therapeutics director Edward T. Mathers received a new stock option grant covering 35,000 shares of common stock. The nonstatutory option has an exercise price of $13.45 per share and expires on June 2, 2036.
According to the terms, the option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders held after that date, as long as Mathers continues to serve as a director, employee, or consultant of Trevi Therapeutics.
Trevi Therapeutics, Inc. reported results of its 2026 annual stockholder meeting, where investors approved several governance and capital measures. Stockholders adopted an Amended and Restated 2019 Stock Incentive Plan, adding 8,000,000 shares of common stock for future equity awards and tightening rules on director pay, share recycling, and dividend treatment on awards.
They also approved an amendment to the restated certificate of incorporation to increase authorized common shares from 200,000,000 to 400,000,000, which became effective upon filing a Certificate of Amendment in Delaware on June 3, 2026. Stockholders elected Michael Heffernan as a Class I director through the 2029 annual meeting, ratified Ernst & Young LLP as independent auditor for the 2026 fiscal year, and gave advisory approval to executive compensation.
Trevi Therapeutics director Dominick Colangelo received a new stock option grant. On the reported date, he was granted a nonstatutory option to buy 35,000 shares of Trevi Therapeutics common stock at an exercise price of $13.45 per share.
The option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders held after that date, as long as he continues to serve as a director, employee or consultant. Following this grant, he holds 35,000 stock options directly.
Trevi Therapeutics, Inc. director David P. Meeker received a grant of a nonstatutory stock option covering 35,000 shares of common stock. The option has an exercise price of $13.45 per share and expires on June 2, 2036.
The option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting held after that date, subject to his continued service as a director, employee or consultant. Following this grant, Meeker holds 35,000 derivative securities directly.
Trevi Therapeutics director Anne Vanlent received a grant of stock options covering 35,000 shares of common stock. The nonstatutory options have an exercise price of $13.45 per share and expire on June 2, 2036. All 35,000 underlying shares are scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders, as long as she continues serving as a director, employee or consultant. Following this award, her reported derivative holdings from this grant total 35,000 options, reflecting a routine compensation-related acquisition rather than an open-market purchase.